Navigation Links
Hormone therapy increases frequency of abnormal mammograms, breast biopsies
Date:2/25/2008

Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies and may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the February 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Hormone therapy use remains common among women beginning menopause, according to background information in the article. For women with a uterus considering combined estrogen plus progestin use, identified breast cancer issues represent a concern, the authors write.

Rowan T. Chlebowski, M.D., Ph.D., of the Los Angeles Biomedical Research Institute at HarborUCLA Medical Center, and colleagues studied 16,608 post-menopausal women who participated in the Womens Health Initiative (WHI) clinical trial, beginning in 1993 through 1998. A total of 8,506 women were randomly assigned to receive a combination of estrogen (0.625 milligrams of conjugated equine estrogens per day) plus progesterone (2.5 milligrams of medroxyprogesterone acetate per day), while 8,102 took a placebo. Each woman received a mammogram and breast examination yearly, with biopsies performed based on physicians clinical judgment.

During the 5.6 years of the study, 199 women in the combined hormone group and 150 women in the placebo group developed breast cancer. Mammograms with abnormal results were more common among women taking hormones than among women taking placebo (35 percent vs. 23 percent); women taking hormones had a 4 percent greater risk of having a mammogram with abnormalities after one year and an 11 percent greater risk after five years.

Breast biopsies also were more common among women taking hormones than among those assigned to placebo (10 percent vs. 6.1 percent). Although breast cancers were significantly increased and were diagnosed at higher stages in the combined hormone group, biopsies in that group less frequently diagnosed cancer (14.8 percent vs. 19.6 percent), the authors write.

After discontinuation of combined hormone therapy, its adverse effect on mammograms modulated but remained significantly different from that of placebo for at least 12 months, they continue.

Use of combined hormones increases breast density, which increases the risk of breast cancer and may also delay diagnosis, the authors note. However, breast density was not measured in the current study.

Use of conjugated equine estrogens plus medroxyprogesterone acetate for approximately five years resulted in more than one in 10 and one in 25 women having otherwise avoidable mammogram abnormalities and breast biopsies, respectively, and compromised the diagnostic performance of both, the authors conclude. This adverse effect on breast cancer detection should be incorporated into risk-benefit discussions with women considering even short-term combined hormone therapy.


'/>"/>

Contact: Laura Mecoy
310-546-5860
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. LA BioMed study finds hormone therapy increases frequency of abnormal mammograms, breast biopsies
2. Hormone refractory prostate cancers more likely to spread to other organs
3. Newly discovered role of thyroid hormone during pregnancy
4. Stress hormone impacts memory, learning in diabetic rodents
5. Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
6. Diabetes, Growth Disorders Drive Sales of Pediatric Hormone Drugs
7. Sex Hormones Dont Seem to Affect Prostate Cancer Risk
8. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
9. FDA Warns Against Bio-Identical Hormone Therapy
10. FDA Asserts New Policy to Restrict Womens Access to Bioidentical Hormones
11. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: